New study tracks prostate Cancer's next move in 396 men
NCT ID NCT07154914
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 30 times
Summary
This study follows 396 men with metastatic hormone-sensitive prostate cancer to see how their cancer evolves and becomes resistant to standard hormone therapy. Participants will receive different treatment combinations, and researchers will track how long it takes for the cancer to stop responding. The goal is to learn which treatments work best and how genetic differences affect outcomes, helping doctors personalize care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.